根据Hypofractionated Treatment Effects in the Clinic（HyTEC）工作组的研究，我们开发了一系列放射生物学模型，用于研究体型定向放射治疗（SBRT）对早期非小细胞肺癌（NSCLC）的肿瘤控制概率（TCP）。本研究旨在通过近期的临床TCP数据验证三个代表性模型，这些数据包括了从常规放射治疗到SBRT对早期NSCLC的范围，并确定模型无关的早期NSCLC放疗1至30次分数的系统最佳分数化配比。我们收集了来自56篇已发表文章的9808名患者的近期临床1年、2年、3年和5年TCP数据，这些数据为2-4Gy每分数的放疗和SBRT对早期NSCLC的治疗提供了基础。这组数据几乎将最初的HyTEC样本数量增加了三倍，用于进一步验证从对临床TCP数据拟合得出的HyTEC模型参数。扩展数据集中的TCP数据通过HyTEC模型很好地描述，其中α/β比例约为20Gy。TCP随着生物有效剂量（BED）的增加而急剧增加，并达到一个渐近最大平台，从而可以确定早期NSCLC放疗的最佳分数化方案。HyTEC放射生物学模型中的α/β比例约为20Gy，该模型通过对SBRT早期NSCLC的临床TCP数据进行拟合，很好地描述了2-4Gy每分数的放疗和SBRT的剂量和分数化方案所得到的最新TCP数据。TCP与BED之间存在陡峭的剂量响应，并且TCP达到一个渐近最大值。这一特征实现了模型无关的最佳分数化方案，并且在1-30次分数的SBRT和低剂量放疗早期NSCLC中实现了渐近最大的肿瘤控制，而T2肿瘤所需的最佳剂量比T1肿瘤略高。所提出的最佳分数化方案与早期NSCLC SBRT的临床实践一致。版权所有©2023。由Elsevier Inc.出版。

A series of radiobiological models were developed to study tumor control probability (TCP) for stereotactic body radiotherapy (SBRT) of early-stage non-small-cell lung cancer (NSCLC) per the Hypofractionated Treatment Effects in the Clinic (HyTEC) working group. This study is to further validate three representative models with the recent clinical TCP data ranging from conventional radiotherapy to SBRT of early-stage NSCLC and to determine systematic optimal fractionation regimens in 1-30 fractions for radiotherapy of early-stage NSCLC which are found to be model-independent.Recent clinical 1-, 2-, 3-, and 5-year actuarial or Kaplan-Meier TCP data of 9808 patients from 56 published papers were collected for radiotherapy of 2-4 Gy per fraction and SBRT of early-stage NSCLC. This dataset nearly triples the original HyTEC sample, which is used to further validate the HyTEC model parameters determined from a fit to the clinical TCP data.TCP data from the expanded dataset are well-described by the HyTEC models with α/β ratios of about 20 Gy. TCP increases sharply with biologically effective dose (BED) and reaches an asymptotic maximal plateau, which allows us to determine optimal fractionation schemes for radiotherapy of early-stage NSCLC.The HyTEC radiobiological models with α/β ratios of about 20 Gy determined from the fits to the clinical TCP data for SBRT of early-stage NSCLC describe the recent TCP data well for both radiotherapy of 2-4 Gy per fraction and SBRT dose and fractionation schemes of early-stage NSCLC. A steep dose response exists between TCP and BED, and TCP reaches an asymptotic maximum. This feature results in model-independent optimal fractionation regimens determined whenever safe for SBRT and hypofractionated radiotherapy of early-stage NSCLC in 1-30 fractions to achieve asymptotic maximal tumor control, and T2 tumors require slightly higher optimal doses than T1 tumors. The proposed optimal fractionation schemes are consistent with clinical practice for SBRT of early-stage NSCLC.Copyright © 2023. Published by Elsevier Inc.